Research ArticleArticle
Functional Loss of the Reduced Folate Carrier Enhances the Antitumor Activities of Novel Antifolates with Selective Uptake by the Proton-Coupled Folate Transporter
Sita Kugel Desmoulin, Lei Wang, Lisa Polin, Kathryn White, Juiwanna Kushner, Mark Stout, Zhanjun Hou, Christina Cherian, Aleem Gangjee and Larry H. Matherly
Molecular Pharmacology October 2012, 82 (4) 591-600; DOI: https://doi.org/10.1124/mol.112.079004
Sita Kugel Desmoulin
Graduate Program in Cancer Biology (S.K.D., L.H.M.) and Departments of Oncology (S.K.D., L.P., K.W., J.K., Z.H., C.C., L.H.M.) and Pharmacology (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan (L.P., Z.H., C.C., L.H.M.); Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan (M.S.); and Division of Medicinal Chemistry, Graduate School of Pharmaceutical Science, Duquesne University, Pittsburgh, Pennsylvania (L.W., A.G.)
Lei Wang
Graduate Program in Cancer Biology (S.K.D., L.H.M.) and Departments of Oncology (S.K.D., L.P., K.W., J.K., Z.H., C.C., L.H.M.) and Pharmacology (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan (L.P., Z.H., C.C., L.H.M.); Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan (M.S.); and Division of Medicinal Chemistry, Graduate School of Pharmaceutical Science, Duquesne University, Pittsburgh, Pennsylvania (L.W., A.G.)
Lisa Polin
Graduate Program in Cancer Biology (S.K.D., L.H.M.) and Departments of Oncology (S.K.D., L.P., K.W., J.K., Z.H., C.C., L.H.M.) and Pharmacology (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan (L.P., Z.H., C.C., L.H.M.); Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan (M.S.); and Division of Medicinal Chemistry, Graduate School of Pharmaceutical Science, Duquesne University, Pittsburgh, Pennsylvania (L.W., A.G.)
Kathryn White
Graduate Program in Cancer Biology (S.K.D., L.H.M.) and Departments of Oncology (S.K.D., L.P., K.W., J.K., Z.H., C.C., L.H.M.) and Pharmacology (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan (L.P., Z.H., C.C., L.H.M.); Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan (M.S.); and Division of Medicinal Chemistry, Graduate School of Pharmaceutical Science, Duquesne University, Pittsburgh, Pennsylvania (L.W., A.G.)
Juiwanna Kushner
Graduate Program in Cancer Biology (S.K.D., L.H.M.) and Departments of Oncology (S.K.D., L.P., K.W., J.K., Z.H., C.C., L.H.M.) and Pharmacology (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan (L.P., Z.H., C.C., L.H.M.); Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan (M.S.); and Division of Medicinal Chemistry, Graduate School of Pharmaceutical Science, Duquesne University, Pittsburgh, Pennsylvania (L.W., A.G.)
Mark Stout
Graduate Program in Cancer Biology (S.K.D., L.H.M.) and Departments of Oncology (S.K.D., L.P., K.W., J.K., Z.H., C.C., L.H.M.) and Pharmacology (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan (L.P., Z.H., C.C., L.H.M.); Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan (M.S.); and Division of Medicinal Chemistry, Graduate School of Pharmaceutical Science, Duquesne University, Pittsburgh, Pennsylvania (L.W., A.G.)
Zhanjun Hou
Graduate Program in Cancer Biology (S.K.D., L.H.M.) and Departments of Oncology (S.K.D., L.P., K.W., J.K., Z.H., C.C., L.H.M.) and Pharmacology (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan (L.P., Z.H., C.C., L.H.M.); Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan (M.S.); and Division of Medicinal Chemistry, Graduate School of Pharmaceutical Science, Duquesne University, Pittsburgh, Pennsylvania (L.W., A.G.)
Christina Cherian
Graduate Program in Cancer Biology (S.K.D., L.H.M.) and Departments of Oncology (S.K.D., L.P., K.W., J.K., Z.H., C.C., L.H.M.) and Pharmacology (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan (L.P., Z.H., C.C., L.H.M.); Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan (M.S.); and Division of Medicinal Chemistry, Graduate School of Pharmaceutical Science, Duquesne University, Pittsburgh, Pennsylvania (L.W., A.G.)
Aleem Gangjee
Graduate Program in Cancer Biology (S.K.D., L.H.M.) and Departments of Oncology (S.K.D., L.P., K.W., J.K., Z.H., C.C., L.H.M.) and Pharmacology (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan (L.P., Z.H., C.C., L.H.M.); Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan (M.S.); and Division of Medicinal Chemistry, Graduate School of Pharmaceutical Science, Duquesne University, Pittsburgh, Pennsylvania (L.W., A.G.)
Larry H. Matherly
Graduate Program in Cancer Biology (S.K.D., L.H.M.) and Departments of Oncology (S.K.D., L.P., K.W., J.K., Z.H., C.C., L.H.M.) and Pharmacology (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan (L.P., Z.H., C.C., L.H.M.); Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan (M.S.); and Division of Medicinal Chemistry, Graduate School of Pharmaceutical Science, Duquesne University, Pittsburgh, Pennsylvania (L.W., A.G.)

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Impact of RFC on PCFT-Targeted Therapeutics
Sita Kugel Desmoulin, Lei Wang, Lisa Polin, Kathryn White, Juiwanna Kushner, Mark Stout, Zhanjun Hou, Christina Cherian, Aleem Gangjee and Larry H. Matherly
Molecular Pharmacology October 1, 2012, 82 (4) 591-600; DOI: https://doi.org/10.1124/mol.112.079004
Research ArticleArticle
Impact of RFC on PCFT-Targeted Therapeutics
Sita Kugel Desmoulin, Lei Wang, Lisa Polin, Kathryn White, Juiwanna Kushner, Mark Stout, Zhanjun Hou, Christina Cherian, Aleem Gangjee and Larry H. Matherly
Molecular Pharmacology October 1, 2012, 82 (4) 591-600; DOI: https://doi.org/10.1124/mol.112.079004
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement